Background: Mitochondrial DNA (mtDNA) mutations are important causes of human genetic disease, with mutations in tRNA genes particularly prevalent. In many patients, mutations are heteroplasmic, affecting a population of mtDNA molecules. Establishing the pathogenicity of homoplasmic mitochondrial tRNA (mt-tRNA) mutations, in which the mutation is present in every mtDNA molecule, is extremely difficult. These mutations must conform to specific pathogenic criteria, documenting unequivocally a functional defect of the mutant mt-tRNA.
Aims: To investigate the pathogenic nature of two homoplasmic mt-tRNAThr deletions, m.15940delT (previously reported as pathogenic) and m.15937delA, by assessing the steady state levels of the mutant mt-tRNA in tissue and cell-line samples from six unrelated families, in which affected individuals were thoroughly investigated for mitochondrial DNA disease on the basis of clinical presentations. Rates of de novo mitochondrial protein synthesis were also examined in control and m.15937delA mutant fibroblasts.
Results: Our data strongly suggest that both single nucleotide deletions are neutral polymorphisms; no obvious defects were apparent in either steady state mt-tRNAThr levels or rates of mitochondrial protein synthesis.
Conclusions: These findings have important implications for the investigation of other families with suspected mtDNA disease, in particular the requirement to fulfil strict and established pathogenic criteria in order to avoid misattribution of pathogenicity to mt-tRNA variants.
Statistics from Altmetric.com
Funding: Funded by the Italian Ministry of Health (FMS), a Fellowship from the Bambino Gesù-Roma3 University joint PhD program (FF), Fondazione Pierfranco e Luisa Mariani (MZ), MITOCIRCLE (MZ), the Marriott Mitochondrial Disorder Clinical Research Fund (SD), the Medical Research Council, UK (RM) and the Wellcome Trust (RWT).
Competing interests: None declared.
Ethics approval: This study was performed under the ethical guidelines issued by each of our institutions for clinical studies.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.